These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18032083)

  • 1. A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro.
    Johansson UB; Wredling R; Adamson U; Lins PE
    Diabetes Metab; 2007 Dec; 33(6):469-71. PubMed ID: 18032083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW; Steed RD; Schleusener DS; Strange P
    Endocr Pract; 2005; 11(3):157-64. PubMed ID: 16239201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
    Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
    Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes.
    Alemzadeh R; Parton EA; Holzum MK
    Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Nutr Metab; 2004 Apr; 17(2):84-9. PubMed ID: 15244099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB; Bode BW; Garg S; Lane WS; Sussman A; Hu P; Santiago OM; Kolaczynski JW;
    Diabetes Care; 2005 Mar; 28(3):533-8. PubMed ID: 15735183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Jan; 23(1):46-52. PubMed ID: 16409565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.
    Fahlén M; Eliasson B; Odén A
    Diabet Med; 2005 Apr; 22(4):382-6. PubMed ID: 15787660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.